![]() |
|
|
Vol. 286, Issue 1, 289-297, July 1998
Immunopharmacology Group, University of Southampton, Southampton
General Hospital, Southampton, SO16 6YD, United Kingdom
Tryptase, the most abundant protein product of human mast cells is
emerging as an important mediator and target for therapeutic intervention in allergic disease. We have investigated the potential of
tryptase and inhibitors of tryptase to modulate histamine release from
human mast cells. Addition of purified human tryptase in concentrations
ranging from 1 to 100 mU/ml stimulated a concentration-dependent release of histamine from cells dispersed from tonsil, although not
from skin tissue. The reaction depended on an intact catalytic site
being inhibited by heat inactivation of the enzyme, or by preincubating
with the tryptase inhibitors APC366 or leupeptin or the tryptic
substrate
N-benzoyl-DL-arginine-p-nitroanilide (BAPNA). Tryptase-induced histamine release took approximately 6 min to
reach completion, appeared to require exogenous calcium and magnesium,
and on the basis of inhibition by antimycin A and 2-deoxy-D-glucose, seemed to be a noncytotoxic process.
Preincubation of cells with tryptase at concentrations that were
suboptimal for histamine release had little effect on their
responsiveness to anti-immunoglobulin (Ig) E or to calcium ionophore
A23187, but at higher concentrations their subsequent activation was
inhibited. APC366 significantly inhibited histamine release induced by
anti-IgE or calcium ionophore from both tonsil and skin cells, with up to 90% inhibition being observed at a concentration of 100 µM with
skin. IgE-dependent histamine release was inhibited also by leupeptin,
benzamidine and BAPNA. Tryptase may act as an amplification signal for
mast cell activation, and this could account at least partly for the
potent mast cell stabilizing properties of tryptase inhibitors.